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Abstract
Smoking and diabetes could both be
prevented if individuals would abstain from smoking,
eat healthy, and exercise regularly. Smokers with
diabetes have an increased risk of serious health
outcomes, hence effective smoking cessation
interventions are critical. The transtheoretical model
was used in this quantitative study analyzing
secondary data from the state of Nevada Quitline to
examine the relationships between smoking cessation
method (counseling versus counseling and
medication) and quitting smoking for 720 smokers
with/without diabetes. Participants were Nevada
residents, ages 18+, men and women, English or
Spanish speakers. Descriptive statistics, logistic
regression, and a test of two proportions were
conducted. The majority of the participants had not
quit (67.5%). Quit rates did not differ between
smokers with/without diabetes, however, individuals
who received counseling and medication were 1.94
times as likely to quit compared to those who
received counseling alone. Among diabetes smokers,
age was significantly related to quit status; for every
1 year, the likelihood of quitting increased by 1.03
times; and Hispanics were 7.50 times more likely to
quit smoking compared to Caucasians. Findings from
this study could help healthcare providers, public
health practitioners, and scholars develop effective
smoking cessation programs to meet the needs of
smokers with diabetes.
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Smoking is one of the most preventable
causes of disease and premature death in the United
States, killing 480,000 people each year (Centers for
Disease and Prevention [CDC], 2012a; U. S.
Department of Health and Human Resources,
[USDHHS], 2014). While it could be prevented,
diabetes, is the seventh leading cause of death in the
United States that results in long term chronic disease
consequences (CDC, 2014b). Smokers with diabetes
are said to be less active compared to smokers
without diabetes (Tonstand, 2009; Solberg, Desai,
O'Connor, Bishop, & Devlin, 2004). The prevalence
of smoking as well as that of diabetes is expected to
grow within the next two decades (Will et al., 2007).
As of 2010, diabetes has been reported to affect 25.8
million people or 8.3% of the U.S. population (CDC,
2011c). By the year 2030, tobacco dependence will
be the cause of 8 million deaths, directly or indirectly
(World Health Organization [WHO], 2012).
According to the CDC, over 100 million people have
died as a result of tobacco use during the 20 th century
and an estimate of 1 billion people could be killed in
the 21st century (CDC, 2011d).
In this study, the researchers examined quit
rates among smokers with diabetes in comparison to
those without diabetes and identified the most
effective smoking cessation method utilized by the
study population. This study intends to promote
positive social change by helping healthcare
providers, public health practitioners, and scholars
develop effective smoking cessation programs for
smokers with and without diabetes. According to the
American Chemical Society ([ACS], 2011), smokers
with diabetes have a higher level of hemoglobin A1c
(HbA1c), which is the gold standard for monitoring
long-term blood sugar levels in people with diabetes.
Therefore, people with diabetes may respond
differently to smoking cessation programs from
people without diabetes; both genetically and
psychologically (ACS, 2011). Psychologically, those
who developed diabetes as a result of their smoking
may be more likely to quit due to more serious
consequences from smoking than others.
The number of individuals with diabetes
continues to grow as a result of the increase in
population, urbanization, aging, and other risk factors
such as obesity and lack of physical activities (Wild,
Roglic, Green, Sicree, & King, 2004). Smokers with
diabetes are less motivated to quit when compared to
the general population (Selby, 2008) and many times
this group of individuals lacks the knowledge,
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awareness, and understanding of smoking cessation
options such as counseling and medications (Gill,
2005). Sherman (2005) recommended that clinicians
should identify and provide combination therapy (i.e.,
counseling and medication) options to smokers with
diabetes. The goal of this study was to: (a). compare
quit rates among smokers with or without diabetes
and (b). identify the most effective smoking cessation
method utilized by smokers with or without diabetes.
The potential positive social change aspect of this
study is that it may provide smokers with diabetes as
well as healthcare professionals with information
about effective smoking cessation methods,
specifically concerning what role counseling alone or
a combination of counseling and medication plays in
helping individuals quit. If they quit, smokers with
diabetes will reduce the risk for heart attack, stroke,
nerve damage, and kidney damage while their blood
pressure, blood circulation, and blood cholesterol
could improve (Selby, 2008; Sherman, 2005;
Steinberg et al., 2008).
Purpose of the Study
The purpose of this study is to investigate
(a) quit rates among smokers with diabetes compared
to smokers without diabetes (b) the association
between quitting smoking and the type of smoking
cessation method used. This quantitative study used
secondary data from the state of Nevada Quitline
(also known as the Nevada Tobacco Users Helpline
[NTUH]) that was previously collected for
counseling and treatment services. The study
described and compared the effectiveness of each
method (e.g., counseling alone [Level II] or a
combination of counseling and medications [Level
III]). The dependent variable was quit status during
the last follow up. The independent variables were:
counseling and a combination of counseling and
medications used.
Theoretical Foundation
This research project tested the effectiveness
of counseling, and a combination of counseling and
medications. The transtheoretical model (TTM) was
used. This model presents five stages that are:
precontemplation, contemplation, preparation, action,
and maintenance (Prochaska & Goldstein, 1991).
TTM is useful for identifying positive social change
and a stage that an individual is in the change process
(Zimmerman, Olsen, & Bosworth, 2000). Also, TTM
allows programs to monitor interventions and provide
constructive feedback that will prevent the subjects
from rushing through the process or moving too slow.
Using the TTM stage-matched, patient-centered
approach can help physicians as well as healthcare
professionals design more effective treatment or

counseling interventions, which reduces treatment
resistance and increase treatment compliance
(Martin, Williams, Haskard, & Di Matteo, 2005;
Prochaska & Goldstein, 1991).
Counseling
For many years, diabetes patients continue
to smoke despite its negative impact on their health.
Diabetes is registered next to other co-morbid health
conditions as a target factor for smoking cessation
treatment as a result of greater risks connected with
this disease and smoking (Tonstand, 2009). The
prevalence of smoking is almost the same among
those with diabetes (27.4%) and those without
diabetes (25.9%; American Diabetes Association
[ADA], 2004; Haire-Joshu et al., 1999; Sherman,
2005; Tonstand, 2009). Most cigarette smokers want
to quit; however, it is hard for them without proper
support and understanding of the existing options that
they have (Steinberg et al., 2008). The role of
counseling is important when it comes to smoking
cessation as cigarette smoking may result in poor
health outcomes especially for persons with diabetes
(Canga et al. 2000; Selby 2008). Therefore,
counseling is thought to be one of the most effective
public health interventions when it comes to smoking
cessation and prevention efforts and this intervention
approach has made a difference in the lives of many
smokers (Selby, 2008).
Medication
Smoking cessation medications increase the
odds of successful quitting as compared to nonmedication cessation efforts (Selby, 2008). The first
seven recommended medications that increase the
chances of long-term abstinence rates are: Nicotine
gum, Bupropion, Nicotine lozenge, Nicotine inhaler,
Nicotine patch, Nicotine nasal spray, and Varenicline
(CDC, n.d; Fiore, Bailey, Cohen, Dorfman,
Goldstein, & Gritz, 2008; Steinberg, et al., 2008;
Tonstand, 2009). A combination of medications is
also recommended just as counseling and medication
is recommended over either method alone (CDC,
n.d.; Selby, 2008; Sherman, 2005; Steinberg, et al.,
2008). A combination of lozenges and gum is
recommended for smokers with diabetes for a period
of up to 12 weeks (Tonstand, 2009). There is limited
data pertaining to the effectiveness of smoking
cessation medications among persons with diabetes
(Tonstand, 2009). Many times smokers with diabetes
have poor performance in terms of knowledge,
awareness, and understanding of smoking cessation
medications (Gill, Morgan, & MacFarlane, 2005).
The state of Nevada Quitline uses over the counter
medications: Gum, Lozenge, and Patches for light
smokers (those who smoke less than 20 cigarettes per
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day), and prescription medication: Nicotine inhaler,
Bupropion, and Varenicline for heavy smokers (those
who smoke a pack a day or higher; NTUH, n.d.). For
light smokers who were in the contemplation or precontemplation stage of change, without a projected
quit date or with a projected quit date farther than 90
days, were recommended counseling and over the
counter medications. For heavy smokers who were in
the preparation stage of change, with a projected quit
date within the next 90 days, were recommended
counseling and prescription medications.
Methods
Data Collection
This study used secondary data from the
state of Nevada Quitline that was previously
collected for service purposes from January 1, 2010
to September 1, 2011 for intake and from July 1,
2010 to March 1, 2012 for the 6 months evaluation
follow-up. The data used were a portion of a larger
dataset of 3,500 quitline callers. However, when data
was cleaned and tested, the final sample size for this
research study was 720 callers, of which 613 had
completed every question used for this study. Using a
quasi-experimental study design, this study
controlled the assignment to the treatment groups by
separating the data for those who received counseling
only (Level II) versus those who received a
combination of counseling and medication (Level
III).
Data was retrieved after an Institutional
Review Board (IRB) approval from Walden
University (#08-14-13-0137985). No identifying
information was gathered. The data collection
instrument consisted of intake information and
evaluation follow-up questions at 6 months. Ethical
guidelines were followed that included: respect of
human subject rights, understanding of their needs,
values, and their desire to participate in the study
(Creswell, 2009, p.198). In order to guarantee the
highest level of confidentiality, all Quitline data
collected is protected under confidentiality laws,
including the Health Insurance Portability and
Accountability Act of 1996 (HIPAA) and the Nevada
Revised Statues (NRS). All data collected from
Quitline callers is stored in a secured web application
(NTUH, n.d.).
Eligibility
The sample population consisted of Nevada
residents, ages 18 years and older, men and women,
English or Spanish speakers, who were enrolled
during the study time frame for free smoking
cessation services from the state of Nevada Quitline

program. Participants had to be current or discharged
smokers (those who have quit and completed the
program) who received Level II or Level III free
Quitline services during the time of their enrollment.
Since the Quitline provides services in English and
Spanish languages, data from study participants who
spoke either or both of the two languages were
included.
Analysis
We used SPSS 22.0 statistical package for
data analysis, including descriptive statistics, logistic
regression, and a test of two proportions in order to
answer the research questions. The p-value
significance level was set at 0.05 and all values that
were equal to or less than 0.05 were considered as
statistically significant. Specifically, the dependent
variable is quit status at last follow up and the
independent variables are the types of smoking
cessation methods utilized. Additional descriptive
variables are also included. The following steps were
used: data preparation, descriptive statistics, and
statistical analyses - as recommended by Trochim
and Donnelly (2008, p. 252). Finally, statistical
analyses of logistic regression, and the test of two
proportions were done in order to test hypotheses and
find answers to the research questions.
Results
Descriptive Statistics
The frequencies and percentages for the
categorical demographic variables are displayed in
Table - Appendix A. More participants were female
(56.8%) than were male (43.2%). The majority of the
participants were Caucasian (66.1%), followed by
African American (15.8%), and Hispanics (14.4%).
Most of the participants intended to quit smoking
within 30 days (94.1%). Only 15.1% of participants
reported calling due to the advice of a physician.
Approximately 60% of participants received
counseling only (61.1%) compared to 38.9% who
received both counseling and medication. Finally,
16.9% of participants reported having diabetes. The
mean age was 47.69 years (SD = 13.48) with a
minimum of 18 years and a maximum of 83 years.
Dependent Variables
The majority of the study participants
indicated "no" to Quitting (67.5%) as compared to
those who indicated "Yes" to Quitting (32.5%).
Research Question 1
Crosstab analyses using Pearson’s chisquare and Cramer’s V tests were conducted to
examine the relationships between diabetes and quit
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status. The relationship between quit status and
diabetes was not significant, p = .618. The proportion
of those with diabetes who had quit was 34.4%,
which was not significantly different than the 32.1%
of those without diabetes who quit.
Research Question 2
A logistic regression analysis was conducted
to predict quit status from the type of smoking
cessation method used, diabetes status, and
covariates, Table 2- Appendix B. Level of service and
diabetes status was entered as block 1 and the other
demographics were added as block 2. Overall, block
1 was significant, p < .001, Nagelkerke R2 = .035.
Level of service was a significant predictor, p < .001,
and had a significant odds ratio of 2.015 indicating
that those who got counseling and medication were
about twice as likely to quit compared to those who
got counseling only. Although overall block 2 was
significant with level of service, diabetes, and the
covariates, p = .021, Nagelkerke R2 = .047, the model
change was not statistically significant, p = .819,
Nagelkerke R2 = .012.
When the predictors in block 2 were
examined solely for the purpose of better
understanding the model, level of service was still a
significant predictor, p < .001, and had an odds ratio
of 1.94. This is very similar to the odds ratio revealed
in block 1. In addition, none of the remaining
predictors (e.g., age, ethnicity, physician advice, or
the readiness to quit assessment questions) were
significant predictors of quit status (ps > .05)
providing further evidence that block 1 should be
used to evaluate hypotheses 2.
Discussion
The relationship between quit status and
diabetes was not significant and this implies that quit
rates were not any different between smokers with
diabetes versus smokers without diabetes. These
findings are supported by the literature whereby
Schauer et al. (2008) and Sherman (2005) reported
that there were no major differences when it comes to
quit rates for those with and without diabetes. The
level of service that smokers received was a
significant predictor of quit status, indicating that
those who got counseling and medication were about
twice as likely to quit compared to those who got
counseling only. Even though many variables were
included into the model, the explained variance in
quitting was minimal at 3.5 to 4.7%. This model
explains very little of the variance in quitting because
there are other factors at work and also because the

quit rates were very similar. Only level of service
was significant for both blocks.
As presented in the literature, clinicians
should provide combination therapy (e.g., counseling
and medication) and offer these options to smokers
with diabetes (Millett, 2007; Sherman, 2005). A
combination of counseling and medication was more
effective than counseling alone in reducing the
prevalence of smoking among diabetics and nondiabetics represented in this study and hence could
reduce the risk of complications for smokers with
diabetes who quit (Millett, 2007; MacAller et al.,
2011; Sherman, 2005; Steinberg et al., 2008). This
study supports that diabetics do not respond
differently to smoking cessation programs than nondiabetics; however, smoking cessation is still crucial
for this population as they experience by far poorer
health outcomes that result in shorter life expectancy
as compared to the general population (Millett et al.,
2007; Will et al., 2007).
Study Limitations
First, data was strictly self-reported and
hence recall bias could have influenced the final
reported information. In this study, participants might
have over or under estimated information about their
diabetes status, quit status, smoking cessation method
used, and whether or not they received physician
advice to quit. Secondly, the study time frame was
relatively short, covering only a total 21 months
worth of data with just one follow-up evaluation at 6
months. Thus, longer study duration with multiple
follow-up evaluations would potentially be beneficial
in identifying statistically significant associations.
Third, data were only used from one study site and
hence this dataset may not be a true representative of
the demographics of the entire state. For example, not
all of the Nevada residents are smokers and not all of
the Nevada residents who smoke actually call the
Quitline. Additional research opportunities that will
collect data or conduct a review of secondary data
from multiple settings are highly encouraged.
Conclusion
This study was conducted to evaluate the
effectiveness of interventions for smoking cessation
among people with diabetes. Healthcare providers
have an opportunity to address and assess for tobacco
use among their diabetes patients during routine
medical care. Healthcare visits should provide
teachable moments when a patient’s worries and
concerns about tobacco use are answered during their
routine medical care (Fiore, Goplerud, & Schroeder,
2012). Research shows that, smokers with diabetes
are less active and often depressed as compared to
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smokers without diabetes, and therefore this
population requires constant monitoring and
encouragement of their smoking cessation efforts
(Solberg, 2004; Tonstand, 2009). In January of 2012,
the Joint Commission's new requirements for
addressing tobacco use in Hospital facilities were
officially launched in the hopes of improving
smoking cessation interventions (Fiore et al., 2012).
The question to whether each and every hospital
follows this rule has yet to be explored; however,
many hospitals are making efforts in training their
employees on how to address tobacco use and
referring their patients to a resource such as their
state Quitline.
Therefore, this study could contribute to the
knowledge that healthcare providers need in order to
create and enforce policies surrounding smoking
cessation specifically among people with chronic
conditions such as smokers with diabetes. Findings
from this research could help healthcare providers,
facilities, hospitals, and organizations improve their
routine practices, thus resulting in the reduction of
the prevalence of smoking among persons with
diabetes. Also, a combination of counseling and
medication was significantly more effective than
counseling alone and therefore, health care providers
should emphasize this method in order to help
smokers with diabetes quit. Overall, this study
provides useful information pertaining to the most
effective smoking cessation methods among smokers
with diabetes. These changes could improve the
quality and quantity of their lives enriching them,
their families as well as their communities.
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Appendices
Appendix A
Table 1
Frequencies and Percentages for categorical demographic variables
___________________________________________________________________________________________
n

%

Gender
Male

310

43.2

Female

408

56.8

Hispanic

104

14.4

African American

114

15.8

Caucasian

476

66.1

26

3.6

656

94.1

6

.9

35

5.0

Yes

109

15.1

No

611

84.9

Level II: Counseling Only

440

61.1

Level III: Counseling and Medication

280

38.9

598
122

83.1
16.9

Race/Ethnicity

Other
Intent to Quit within 30 Days (from Intake)
Yes
No
Unsure
Physician Advice

Smoking Cessation Method

Diabetes
No
Yes
Note. Frequencies not summing to N = 720 reflect missing data.
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Appendix B
Table 2
Logistic regression predicting quit status from smoking cessation method, diabetes, and covariates
B

SE

Wald

OR

p

Level III: Counseling and Medicationa

.701

.17

17.71

2.016

< .001

Diabetesb

.205

.22

.90

1.228

.342

Level III: Counseling and Medicationa

.661

.17

15.39

1.938

< .001

Diabetesb

.175

.22

.64

1.191

.424

Age

.008

.01

1.49

1.008

.223

Hispanicc

.060

.24

.06

1.062

.807

African Americanc

.240

.23

1.12

1.271

.290

Other Ethnicityc

.025

.48

.00

1.025

.959

Physician Adviced

-.268

.24

1.26

.765

.261

How important is it that you quit using tobacco? e
How sure are you that you will be able to quit using
tobacco even in stressful situations? e
How sure are you that you will be able to quit
tobacco, using our program? e

-.001

.21

.00

.999

.997

.001

.21

.00

1.001

.996

.081

.19

.19

1.085

.660

How committed are you to quit using tobacco? e
How confident are you that you will be able to quit
tobacco this time? e

-.229

.18

1.64

.795

.201

.135

.19

.50

1.145

.481

Block 1

Block 2

Note. Block 1: χ2 (2) = 17.98, p < .001, Nagelkerke R2 = .035. Block 2: χ2 (12) = 23.94, p = .021, Nagelkerke R2 =
.047. Model change: χ2 (10) = 5.96, p = .819, Nagelkerke R2 = .012. acompared to counseling only; bcompared to no
diabetes; ccompared to Caucasian; dcompared to no physician advise; csomewhat/very compared to not at all/not
very/not sure.

